Captor Therapeutics Publishes Q1 2023 Financial Results
May 30, 2023 08:00 ET
|
Captor Therapeutics
Lead asset CT-01 on track for clinical trial application authorization in Q3 2023 Collaboration with Ono Pharmaceuticals in neurological diseases progressing according to planSolid cash position...
Ryvu Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 16, 2023 11:58 ET
|
Ryvu Therapeutics
Updated Clinical Data from the Ongoing Phase Ib Dose-Escalation Study of RVU120 in Patients with AML or High-Risk MDS and Preclinical Data from the Combination Study of RVU120 and Ruxolitinib in...
Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress
May 11, 2023 11:16 ET
|
Ryvu Therapeutics
Updated Clinical Data from the Ongoing Phase 1b Dose-Escalation Study of RVU120 in Patients with AML or High-Risk MDS Show Favorable Safety and Promising Signs of EfficacyPoster Presentation to...
Leading Mobile Game Developer Cherrypick Games Appoints ÜberStrategist as Global PR and Marketing Agency
May 11, 2023 09:00 ET
|
Cherrypick Games
WARSAW, Poland, May 11, 2023 (GLOBE NEWSWIRE) -- Cherrypick Games, creator of globally successful mobile video games, has selected award-winning international agency ÜberStrategist to lead its...
Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress
March 30, 2023 03:00 ET
|
Molecure
Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress Entering 2023 with strong momentum and a robust pipeline of proprietary, first-in-class compoundsFirst...
Captor Therapeutics Discloses Molecular Targets of Pipeline’s Lead Assets and Invites Stakeholders to Webcast
March 28, 2023 02:00 ET
|
Captor Therapeutics
CT-01 targets 3 well suited proteins including NEK7 with poor prognosis in key liver cancerStrong preclinical data generated with CT-02 against NEK7CT-05 potential best-in-class profile in high...
Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 24, 2023 03:30 ET
|
Ryvu Therapeutics
Signed a collaboration agreement with BioNTech to develop and commercialize immunomodulatory small molecule therapeutics; deal terms included €20M upfront payment, €20M equity investment in Ryvu,...
Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer
March 08, 2023 09:00 ET
|
Molecure
Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer OATD-02 is an oral, potent and selective dual arginase...
Captor Therapeutics Announces Three-Year Strategic Objectives
March 07, 2023 02:00 ET
|
Captor Therapeutics
WROCŁAW, Poland, March 07, 2023 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (“Captor”) (WSE:CTX), a leader in the development of Targeted Protein Degradation (TPD)-based drugs, today announced its...
Ryvu Therapeutics to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel and 12th Annual LifeSci Partners Corporate Access Event
January 05, 2023 07:00 ET
|
Ryvu Therapeutics
KRAKOW, Poland, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...